Target Information
General Information of This Target
| Target ID | PATR0NRQPL |
|||||
|---|---|---|---|---|---|---|
| Target Name | Glycylpeptide N-tetradecanoyltransferase 1 (NMT1) |
|||||
| Gene Name | NMT1 |
|||||
| Gene ID | ||||||
| Synonym | Myristoyl-CoA:protein N-myristoyltransferase 1; Peptide N-myristoyltransferase 1; Protein-lysine myristoyltransferase NMT1 |
|||||
| Sequence |
MADESETAVKPPAPPLPQMMEGNGNGHEHCSDCENEEDNSYNRGGLSPANDTGAKKKKKK
QKKKKEKGSETDSAQDQPVKMNSLPAERIQEIQKAIELFSVGQGPAKTMEEASKRSYQFW DTQPVPKLGEVVNTHGPVEPDKDNIRQEPYTLPQGFTWDALDLGDRGVLKELYTLLNENY VEDDDNMFRFDYSPEFLLWALRPPGWLPQWHCGVRVVSSRKLVGFISAIPANIHIYDTEK KMVEINFLCVHKKLRSKRVAPVLIREITRRVHLEGIFQAVYTAGVVLPKPVGTCRYWHRS LNPRKLIEVKFSHLSRNMTMQRTMKLYRLPETPKTAGLRPMETKDIPVVHQLLTRYLKQF HLTPVMSQEEVEHWFYPQENIIDTFVVENANGEVTDFLSFYTLPSTIMNHPTHKSLKAAY SFYNVHTQTPLLDLMSDALVLAKMKGFDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYN WKCPSMGAEKVGLVLQ Click to Show/Hide
|
|||||
| Family | the NMT family |
|||||
| Function |
Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins. Also able to mediate N-terminal lysine myristoylation of proteins: catalyzes myristoylation of ARF6 on both 'Gly-2' and 'Lys-3'. Lysine myristoylation is required to maintain ARF6 on membranes during the GTPase cycle.
Click to Show/Hide
|
|||||
| Uniprot Entry | ||||||
| HGNC ID | ||||||
| KEGG ID | ||||||
Full List of The ADC Related to This Target
Investigative
| ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
|---|---|---|---|---|---|---|
MYX2449 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
N-Myristolytransferase inhibitor (NMTi) |
Undisclosed |
[1] |
Investigative
| ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
|---|---|---|---|---|---|---|
ZA202500415A-ADC Example 1 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NMT inhibitor 1 |
ZA202500415A-ADC-Example-1-Linker |
[2] | |
ZA202500415A-ADC Example 2 |
Rituximab |
B-lymphocyte antigen CD20 (MS4A1) |
NMT inhibitor 1 |
ZA202500415A-ADC-Example-1-Linker |
[2] | |
ZA202500415A-ADC Example 3 |
Sacituzumab |
Tumor-associated calcium signal transducer 2 (TACSTD2) |
NMT inhibitor 1 |
ZA202500415A-ADC-Example-1-Linker |
[2] | |
ZA202500415A-ADC Example 4 |
Ifinatamab |
CD276 antigen (CD276) |
NMT inhibitor 1 |
ZA202500415A-ADC-Example-1-Linker |
[2] | |
ZA202500415A-ADC Example 5 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NMT inhibitor 26 |
ZA202500415A-ADC-Example-1-Linker |
[2] | |
ZA202500415A-ADC Example 6 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
ZA202500415A-ADC-Example-6-payload |
ZA202500415A-ADC-Example-1-Linker |
[2] | |
ZA202500415A-ADC Example 7 |
Trastuzumab |
Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
NMT inhibitor 1 |
Mc-Gly-Gly-Phe-Gly |
[2] |
References